Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.10
Bid: 8.70
Ask: 9.50
Change: -0.15 (-1.62%)
Spread: 0.80 (9.195%)
Open: 9.25
High: 9.25
Low: 9.10
Prev. Close: 9.25
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: FirstGroup extends takeover date; Tasty repays debt

Thu, 23rd Jun 2022 21:28

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

FirstGroup PLC - Aberdeen, Scotland-based transport provider - Extends 'put up or shut up' deadline for I Squared Capital Advisors takeover offer to July 21. On Thursday last week, it said it rejected a possible takeover offer from I Squared Capital Advisors, saying the firm cash component undervalues the company and the contingent component doesn't give shareholders enough certainty. On Thursday, says: "The board, having carefully evaluated the proposal from I Squared, concluded that the proposal significantly undervalued FirstGroup's continuing operations and its future prospects, and was not in a structure that provided sufficient certainty to shareholders." The extension, firm says, will allow "discussions to continue".

----------

Persimmon PLC - York, England-based housebuilder - Picks date for new Chief Financial Officer Jason Windsor to start, naming July 11 as the all-important date. Appointed Windsor as its new CFO from insurer Aviva PLC to succeed Mike Killoran, who will be retiring in mid-January.

----------

Henderson Opportunities Trust PLC - aims to achieve capital growth in excess of the FTSE All-Share index from a portfolio of UK investments - Net asset value per share ends April 30 at 1,471.5 pence, sliding from 1,626.9p six months earlier. Raises dividend to 14.0p from 13.0p a year prior. NAV total return in the first half negative 8.7%, underperforming its benchmark, the FTSE All-Share Index, which adds 3.2%. Chair Wendy Colquhoun says performance was "disappointing". Adds: "While the company's portfolio saw some benefit from its holdings in natural resource companies, this was more than offset by the significant de-rating of many small and medium sized companies. This size differential in how companies performed was among the key drivers of the company's underperformance. In this respect we are, to a degree, comforted that the decline in the company's NAV of 8.7% was less than that of the AIM All-Share Index at 16.0% where just over half of the company's portfolio was invested at the period end."

----------

JPMorgan Japan Small Cap Growth & Income PLC - investment company focused on Japan small caps - Net asset value per share ends March 31 at 397.6 pence, sliding from 550.0p at same point year prior. Annual dividend drops to 20.3p from 21.9p. Annual NAV return negative 25%, underperforming benchmark, the MSCI Japan Small Cap Index, which sees negative 8.1% return. "This underperformance was the result of the portfolio's focus on quality and growth stocks," company says. "As in other major markets, high growth stocks, especially in the technology sector, were hit especially hard as investors focused on rising interest rates, spiralling inflation and the tragic events in Ukraine and tended to ignore the fundamental operational performance of businesses. Japanese growth stocks were caught up in this sell-off, even though inflation in Japan remains very low and the Bank of Japan is unlikely to raise interest rates in the foreseeable future."

----------

Puma VCT 12 PLC - venture capital trust managed by Puma Investments - Shares suspended ahead of general meeting where shareholders will vote on resolution to effect the commencement of the winding up of the trust.

----------

Immediate Acquisition PLC - AIM-listed cash shell, formally Immedia Group PLC - Plans to relist shares after its reverse takeover of Fiinu Holdings Ltd. Expects to have market cap of GBP53 million after relisitng, with 265.1 million shares in issue. Relisting will be July 8. Will be renamed Fiinu Group PLC. Fiinu intends to be a provider of a consumer banking product, the Plugin Overdraft, which will provide an overdraft facility without having to change their current account or request an overdraft from their existing bank.

----------

Aseana Properties Ltd - Jersey-based property development company - Corrects that Director Christopher Lovell was not re-elected at its general annual meeting on June 17, after having previously reported he did. As a result, Lovell retires as a director with immediate effect. Lovell originally joined the company as independent non-executive director in March 2007, before retiring at the 2018 annual general meeting. He returned to the company as non-executive director in June 2019.

----------

Regional REIT Ltd - London-based real estate investment trust - Makes three separate investments in Sheffield city centre, Thorpe Business Park, Leeds, and Leeds city centre for GBP8.5 million, GBP8.6 million, and GBP9.4 million, respectively, reflecting attractive net initial yields of 9.2%, 7.1% and 7.7%, with an overall blended net initial yield of 8.0%. Chief Executive Stephen Inglis says: "The three acquired assets announced today are high quality and well located buildings, purchased at a strong accretive blended yield of 8.0%. All three assets are supported by high quality tenants in a growth region of the UK that we are keen to increase the portfolio's exposure to. The assets also provide us with compelling opportunities to drive further value through asset management activity, whilst delivering attractive income streams."

----------

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Plans to develop GlyMab antibodies into T cell redirecting bispecific antibodies and take them into the clinic. "This is a promising new therapeutic approach to treat cancer," company says. "TCB antibodies have dual-binding specificity which crosslinks tumour cells via their glycans with an activating receptor CD3 on T cells. This results in activation of killer T cells and tumour cell death." Will utilise the GlyMab platform to deliver cytotoxic drugs or cell therapies.

----------

Tasty PLC - London-based casual dining restaurant operator - Repays, in full, GBP1.3 million four year term loan from its existing bankers Barclays Bank. Now has net cash balance of GBP8.6 million with no debt. Adds: "The board believes that, with its current net cash and future cashflow, it will have sufficient funds to weather the prevailing economic uncertainties and cost pressures and also satisfy its measured expansion plans for a pipeline of up to five to six new units in 2022."

----------

Avation PLC - Singapore-based passenger aircraft leasing company - Says Norwegian-owned Swedish airline customer Braathens Regional Airlines collaborates to enable the first ever flight with 100% sustainable fuel in both engines on a commercial aircraft. Executive Chair Jeff Chatfield says: "Avation owns 28 purchase rights over new future delivery ATR72-600 aircraft. Avation believes the sustainable aviation fuel is important because CO2 emissions are reduced by up to 80% compared to non-sustainable jet fuel. Avation is transitioning to become a lessor of climate friendly low CO2 emission aircraft."

----------

Fonix Mobile PLC - London-based mobile payments and messaging provider - Says certain directors, shareholders and employees of the firm sells 6.7 million shares, representing 6.7% of issues share capital, at 150 pence each. Sellers includes Chief Executive Robert Weisz, who offloaded 8.5 million shares. Company notes the placing was to satisfy strong institutional demand. Adds: "Following a series of meetings with both new and existing institutional investors, it became apparent that demand for the ordinary shares was in excess of those readily available for sale. The selling shareholders recognise the strategic importance of a strong and supportive institutional shareholder base, and have therefore decided to release a portion of their own holdings in order to help satisfy this demand."

----------

Light Science Tech Holdings PLC - environment agriculture and technology and contract electronics manufacturing company - Expands nurturGROW lighting product portfolio with the launch of its 'slimline' Vertical Farm range. "Vertical Farm range, which is ideal for cultivation, is designed to maximise space within a vertical/city farm, container or research centre - broadening the reach of nurturGROW's solutions, which currently predominantly target glasshouse and polytunnel growers," it adds.

----------

Good Energy Group PLC - Chippenham, England-based renewable energy supplier - Notes resolutions 8 and special resolutions 9, 10,11 and 12 did not pass at annual general meeting. "Resolutions 9,10 and 11 were relatively standard authorities that UK listed companies take at annual general meetings, relating to the allotment of 5% of shares for cash on a non-pre-emptive basis and purchase of own shares. Resolution 12 was included to amend the Articles of Association to permit hybrid meetings for in person and virtual attendance at general meetings," company says. "The board is disappointed not to receive this limited additional flexibility to pursue opportunities in the interests of the company and its shareholders and to ensure general meetings can be accessible by all in future."

----------

Technology Minerals PLC - London-based company focused on creating a circular economy for battery metals - Its 49%-owned battery recycling business, Recyclus Group Ltd, receives three lithium battery testbed systems, which it says is designed to measure a range of different battery chemistries of different sizes at its Wolverhampton site. "The LIB testbeds give Recyclus the operational capability to test the effective capacity of battery packs from a range of EV and industrial usages as well as for degradation or damage at the cell level. By charging and discharging batteries to measure capacity and capture stored energy it can also perform a number of other critical performance test criteria," it adds.

----------

Southern Energy Corp - oil and gas company focussed on the US state of Mississippi - Raises about USD30.0 million from issue of 26.1 million shares from prospectus offering and placing of 18.7 million shares. Will use net proceeds for capital expenditures to extend and accelerate its planned drilling programme at Gwinville and for general working capital purposes. Further drilling at Gwinville expects to being in the fourth quarter. Notes all three of the horizontal wells from the Gwinville 19-3 padsite are now flowing to sales at highly restricted rates. The padsite is currently producing approximately 15.3 million standard cubic feet per day of natural gas and all three wells are meeting company's early-time expectations.

----------

Atlantic Lithium Ltd - developing Ewoyaa lithium mine in Ghana - "Pleased" with initial assay results from reverse circulation drilling at the Grasscutter North target at the Ewoyaa project in Ghana. Drill intersections include 22 metres at 1.25% lithium oxide from 104 metres and 15 metres at 1.35% lithium oxide from 71 metres. "These results, being in close proximity to the currently defined resource, give us confidence to deliver future resource upgrades for the project," Chief Executive Lennard Kolff says.

----------

Cornish Metals Inc - Vancouver-based mineral exploration company - For three months to April 30 loss narrows to CAD979,427, about GBP615,609, from CAD1.3 million in same period a year prior. Operating expends falls to CAD627,115 from CAD894,549, results in net loss in quarter of CAD625,384 versus CAD908,981 loss the year before. Chief Executive Richard Williams says: "The next few months will be hard but rewarding work as we build the required framework for strong and capable project execution. I look forward to reporting on progress at South Crofty in due course." Notes backdrop for tin pricing in the medium to long term "remains favourable".

----------

Anglo Asian Mining PLC - gold, copper and silver producer focused in Azerbaijan - Notes making good progress at our restored contract area of Vejnaly with mining due to start later this month. Chief Executive Reza Vaziri, at annual general meeting, says "encouraged" by the developments over the past year and believes it has a "solid foundation for further future growth".

----------

Ariana Resources PLC - exploration firm with interests in Turkey - Says its Tavsan project development is being transitioned into the construction stage, with a revised mineral resource estimate and feasibility study underway. Notes, also, diamond drilling programmes underway at Kiziltepe, for up to about 14,000 metres, and at Salinbas, for an extended programme which will involve several drilling rigs. "Significant progress is being made across the Company's projects and interests in south-eastern Europe and further afield," Managing Director Kerim Sener adds.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
31 Oct 2022 16:46

Scancell enrols and doses first patient in latest cancer trial

(Sharecast News) - Immunotherapy developer Scancell announced on Monday that the first patient in the expansion phase of the monotherapy arms in the multicentre phase one clinical trial of 'Modi-1', dubbed 'ModiFY', had been enrolled and dosed.

Read more
28 Oct 2022 14:42

Scancell losses widen on expense of ongoing trials

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell reported an operating loss of £13.3m in its final results on Friday, widening from £8.8m year-on-year, which it put down to the expense of its three ongoing clinical trials.

Read more
28 Oct 2022 11:57

IN BRIEF: Scancell narrows annual loss as vaccine candidates progress

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to GBP3.8 million from GBP16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of GBP7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.

Read more
26 Oct 2022 14:30

IN BRIEF: Scancell executive chair and co-founder both to depart

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Both the executive chair and the company's co-founder will leave the board, while Scancell promotes a non-executive director to deputy chair. Lindy Durrant, also a co-founder, remains chief executive officer. John Chiplin will step down as executive chair and as a director once a new chair is found, having led the board for six years. Richard Goodfellow will retire as non-executive director at the next annual general meeting. Scancell holds its AGMs in November. Goodfellow is a co-founder of Scancell and was its CEO until 2017. Susan Clement Davies will be deputy chair.

Read more
25 Oct 2022 14:34

Scancell inks licensing deal with Nasdaq-traded Genmab

(Sharecast News) - Immunotherapy developer Scancell announced a licensing agreement with the Nasdaq-listed Genmab on Tuesday, to develop and commercialise a Scancell investigational anti-glycan monoclonal antibody into novel therapeutic products.

Read more
25 Oct 2022 12:17

LONDON MARKET MIDDAY: Sterling strength keeps FTSE 100 in red

(Alliance News) - Stocks were mixed in London in midday trade on Tuesday, with the FTSE 100 suffering a bit against a strong pound, which is getting support as Rishi Sunak takes control in Westminster.

Read more
25 Oct 2022 10:44

AIM WINNERS & LOSERS: Scancell signs deal; Empire Metals seeks copper

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
25 Oct 2022 10:03

Scancell shares rocket on potentially lucrative Genmab licensing deal

(Alliance News) - Scancell Holdings PLC shares soared on Tuesday, as the cancer immunotherapies developer announced a licensing agreement with biotechnology company Genmab.

Read more
23 Sep 2022 13:31

Scancell presents new, positive data on possible cancer therapies

(Sharecast News) - Immunotherapy developer Scancell was presenting two posters at the EuroMAbNet 12th annual meeting in Hamburg on Friday, with the first highlighting new data on its 'AvidiMab' and 'GlyMab' technologies.

Read more
16 Aug 2022 17:51

IN BRIEF: Scancell doses first patient in Modi-1 cancer trial

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says first patient is dosed in cohort two of the multicentre phase I Modify trial, for Modi-1, its prospective cancer treatment. The trial will administer Modi-1 alone or with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours. Modi-1 is the first candidate from the firm's Moditope platform.

Read more
23 Jun 2022 12:38

Scancell developing 'promising' new cancer treatment approach

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that it will develop 'GlyMab' antibodies into T-cell redirecting bispecific (TCB) antibodies, and take them into the clinic as a "promising new therapeutic approach" to treat cancer.

Read more
15 Jun 2022 15:58

Scancell updates protocol for UK trial in melanoma patients

(Sharecast News) - Immunotherapy developer Scancell updated the market on the phase 2 'SCOPE' clinical trial in melanoma patients on Wednesday, being conducted at multiple centres in the UK.

Read more
15 Jun 2022 12:19

Scancell shares jump as phase 2 trial of skin cancer drug expands

(Alliance News) - Scancell Holdings PLC on Wednesday said its phase 2 trial of its SCIB1 vaccine in metastatic melanoma patients has expanded, following regulatory approval.

Read more
13 Jun 2022 20:42

IN BRIEF: Scancell says first patient dosed in Modi-1 trial for cancer

Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - Says the first patient in its multicentre Modi-1 clinical trial has been dosed at Imperial College London, Hammersmith Hospital. The study, it explains, is a first-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer, and renal cancer. Modi-1 will be administered alone or in combination with checkpoint inhibitors in patients with head and neck, triple negative breast and renal tumours.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.